Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: The risk of subsequent isolation of multidrug-resistant organisms

      A retrospective cohort study was performed on 175 adult patients treated for community-acquired pneumonia with moxifloxacin or ceftriaxone/azithromycin in a nonintensive care unit. Both cohorts were very similar with regard to a wide range of characteristics including age, severity of disease, comorbidities, length of stay, and mortality. Multidrug-resistant organisms were subsequently isolated from 6 (15%) moxifloxacin-treated patients and 5 (4%) ceftriaxone/azithromycin-treated patients within 90 days after beginning of therapy (P = .026 on logistic regression analysis).

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mandell L.A.
        • Wunderink R.G.
        • Anzueto A.
        • Bartlett J.G.
        • Campbell G.D.
        • Dean N.C.
        • et al.
        Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.
        Clin Infect Dis. 2007; 44: S27-S72
        • Ruhe J.
        • Mildvan D.
        Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?.
        Infect Dis Clin North Am. 2013; 27: 115-132
        • Paterson D.L.
        “Collateral Damage” from cephalosporin or quinolone antibiotic therapy.
        Clin Infect Dis. 2004; 38: S341-S345
        • Weber S.G.
        • Gold H.S.
        • Hooper D.C.
        • Karchmer A.W.
        • Carmeli Y.
        Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients.
        Emerg Infect Dis. 2003; 9: 1415-1422
        • Wener K.M.
        • Schechner V.
        • Gold H.S.
        • Wright S.B.
        • Carmeli Y.
        Treatment with fluoroquinolones or with β-lactam-β-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-β-lactamase-producing Klebsiella species in hospitalized patients.
        Antimicrob Agents Chemother. 2010; 54: 2010-2016
        • Yip C.
        • Loeb M.
        • Salama S.
        • Moss L.
        • Olde J.
        Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea.
        Infect Control Hosp Epidemiol. 2001; 22: 572-575
        • Tacconelli E.
        • De Angelis G.
        • Cataldo M.A.
        • Mantengoli E.
        • Spanu T.
        • Pan A.
        • et al.
        Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study.
        Antimicrob Agents Chemother. 2009; 53: 4264-4269
        • Lodise T.P.
        • Kwa A.
        • Cosler L.
        • Gupta R.
        • Smith R.P.
        Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
        Antimicrob Agents Chemother. 2007; 51: 3977-3982
        • Magiorakos A.P.
        • Srinivasan A.
        • Carey R.B.
        • Carmeli Y.
        • Falagas M.E.
        • Giske C.G.
        • et al.
        Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.
        Clin Microbiol Infect. 2012; 18: 268-281
        • Upadhyay S.
        • Niederman M.S.
        Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia?.
        Infect Dis Clin North Am. 2013; 27: 9-31